Blumberg Capital

Blumberg Capital is a global early-stage venture firm headquartered in San Francisco with a substantial presence in Tel Aviv, and a long track record of backing B2B software, AI, data infrastructure, and security companies. The firm’s healthcare activity sits inside that broader thesis rather than as a separate vertical fund, which shapes how it evaluates digital health and healthcare AI deals: as enterprise software businesses with healthcare as the buyer rather than as healthcare investments first.

The relevant thesis for AI healthcare founders is that Blumberg looks for companies whose underlying technology, often AI, data infrastructure, or workflow automation, would be defensible regardless of vertical, and where healthcare happens to be a particularly attractive market because of buyer pain and willingness to pay. Companies serving providers, payers, life sciences, and clinical research with software that has clear unit economics and a real data advantage tend to fit. Pure consumer wellness, medical devices, and biotech are not core.

Check sizes range from $1M to $5M at entry, primarily at seed and Series A. The firm leads and co-leads, with meaningful reserves for follow-on. Geography spans the US and Israel, with portfolio companies often combining Israeli engineering with US commercial operations. Syndicate partners typically include other US enterprise software VCs and Israeli specialists, and the firm’s network across CIO and CISO buyer communities is useful for healthcare founders selling enterprise contracts.

The team includes investment partners with backgrounds in enterprise software investing, operating roles, and the US-Israel corridor. Board engagement is standard at seed and Series A, with active help on enterprise go-to-market, hiring, and downstream financing. The firm is comfortable supporting founders through the long cycle typical of enterprise healthcare deals.

Founders should approach Blumberg when their product is fundamentally enterprise software, when AI or data infrastructure is the substantive engine, and when the healthcare angle is a deliberate go-to-market choice rather than a vertical accident. Introductions through portfolio CEOs, US and Israeli enterprise software VCs, or operators in the AI infrastructure space are the highest-signal path. The right moment to engage is when the team is technically strong, the product is in market or near it, and the founders can speak fluently about enterprise sales motion, design partners, and unit economics. Founders pitching consumer health, devices, or biotech will not find fit. Pure clinical workflow tools without an enterprise software backbone are also outside the natural mandate. For founders building genuinely strong B2B software with AI at the core and healthcare as the chosen market, Blumberg offers capital, enterprise expertise, and a useful US-Israel posture.